CatalYm is developing innovative immunotherapies to transform cancer patients’ lives by effectively engaging their own immune systems to combat this malignant disease.
Targeting novel mechanisms that lead to a potent and sustained activation of the immune system within the tumor microenvironment, CatalYm’s goal is to rapidly bring its next-generation immuno-oncology products to patients in need.
The company believes its approach will overcome major limitations of existing immunotherapies and will improve cancer patient survival and quality of life. CatalYm is led by an experienced management team of serial biotechnology entrepreneurs and backed by a consortium of blue-chip investors.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.